Amendments to the Claims

Please amend claims 1, 8-10, 14-16, 18, 20, 22, 24 and 27-29 as follows. Please cancel claims 17 and 21 without prejudice. This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently amended) A method of therapeutically or prophylactically treating graft versus host disease (GVHD), including the steps of said method comprising:
- (i) administering a pharmaceutically-effective amount of chaperonin 10 (cpn10) or a derivative of cpn10 to a donor animal or cell, organ or tissue obtained therefrom; and
- (ii) administering to a recipient animal a pharmaceutically-effective amount of cpn10 or a derivative of cpn10, to thereby delay, ameliorate, suppress or otherwise reduce one or more symptoms of GVHD following transplantation of the one or more cells, tissues or organs **from the donor animal** to the recipient animal.
- 2. (Original) The method of claim 1 wherein a pharmaceutically-effective amount of chaperonin 10 or a derivative of cpn10 is administered to a recipient animal both before and after step (ii).
- 3. (Original) The method of claim 1 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the donor and recipient animals for no more than 7 days prior to step (ii).
- 4. (Original) The method of claim 1 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the donor and recipient animals for 2 to 5 days prior to step (ii).
- 5. (Original) The method of claim 1 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the recipient animal for no more than 90 days after step (ii).

- 6. (Original) The method of claim 5 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the recipient animal for no more than 60 days after step (ii).
- 7. (Original) The method of claim 6 wherein a pharmaceutically-effective amount of cpn10 or a derivative of cpn10 is administered to the recipient animal for 10 to 30 days after step (ii).
- 8. (Currently amended) The method of any one of claims 1 to 7 claim 1 wherein said cpn10 protein has an amino acid sequence set forth in FIG. 1 (SEQ ID NO:1).
- 9. (Currently amended) The method of claim 1 wherein the pharmaceutically-effective amount of cpn10 or derivative of cpn10 administered to an animal is within the range 0.1-100 mg/kg body per kg/body weight.
- 10. (Currently amended) The method of claim 9 wherein the pharmaceutically-effective amount of cpn10 or derivative of cpn10 administered to an animal is within the range 0.1-10 mg/kg body per kg/body weight.
- 11. (Original) The method of claim 1 wherein the cell, tissue or organ is, or is derived from, bone marrow.
 - 12. (Original) The method of claim 1 wherein said animal is a mammal.
 - 13. (Original) The method of claim 12 wherein said mammal is a human.
- 14. (Currently amended) The method of claim 1 further including the step of comprising administering to said donor animal and/or said recipient animal at least one other immunosuppressive agent selected from the group consisting of cyclosporin, tacrolimus, sirolimus, mycophenolate, mofetil and methotrexate.
- 15. (Currently amended) The method of claim 1 further including the step of comprising administering to said donor animal and/or recipient animal a steroid.

- 16. (Currently amended) A method of inhibiting, suppressing or otherwise reducing TNFα production in an animal <u>or by one or more cells, tissues or organs obtained from said animal, said method comprising including the step of administering to said animal <u>or said cells, tissues or organs obtained therefrom</u> a pharmaceutically-effective amount of cpn10 or derivative of cpn10 to thereby inhibit, suppress or otherwise reduce production of TNFα in said animal or said cells, tissues or organs obtained therefrom.</u>
 - 17. (Cancelled)
- 18. (Currently amended) The method of claim 16 or claim 17 wherein said animal is a mammal.
 - 19. (Original) The method of claim 18 wherein said mammal is a human.
- 20. (Currently amended) A method of inducing, augmenting or otherwise increasing IL-10 production in an animal <u>or by one or more cells, tissues or organs</u> <u>obtained from said animal, said method comprising including the step of</u> administering to said animal <u>or said cells, tissues or organs obtained therefrom</u> a pharmaceutically-effective amount of cpn10 or derivative of cpn10 to thereby induce, augment or otherwise increase production of ID-10 in said animal <u>or said cells, tissues or organs obtained</u> <u>therefrom</u>.
 - 21. (Cancelled)
- 22. (Currently amended) The method of claim 20 or claim 21 wherein said animal is a mammal.
 - 23. (Original) The method of claim 22 wherein said mammal is a human.
- 24. (Currently amended) A pharmaceutical composition for use according to the method of claims 1, 16 or 17 comprising a pharmaceutically-effective amount of cpn10 or a derivative of cpn10, and a pharmaceutically-acceptable carrier, excipient or diluent.

- 25. (Original) The pharmaceutical composition of claim 24 further comprising at least one other immuunosuppressive agent.
- 26. (Original) The pharmaceutical composition of claim 25 wherein the other immunosuppressive agent is an immunosuppressive drug or a specific antibody directed against B or T lymphocytes or surface receptors that mediate their activation.
- 27. (Currently amended) The pharmaceutical composition of claim 25 wherein the other immunosuppressive agent is any one selected from the group consisting of cyclosporin, tacrolimus, sirolimus, mycophenolate mofetil and methotrexate.
- 28. (Currently amended) The pharmaceutical composition of any one of claims

 24 to 27 claim 24 further comprising a steroid.
- 29. (Currently amended) The pharmaceutical composition of **any preceding** claim **24** wherein cpn10 has an amino acid sequence set forth in FIG. 1 (SEQ ID NO:1).